HCW Biologics Inc. (HCWB) stock
HCWBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3095% below fair value
$0.76−0.01 (-1.65%)
Close on Nov 18, 2026Market cap $1.40MP/E –Yield –
HCW Biologics r&d expenses
Research and development expenses are spending on new products and technology.
HCW Biologics's R&D Expenses for the twelve months ending Jun 30, 2026 was $5.20M, up 5.2% year over year. For fiscal 2025 it was $5.44M, down 14.8% from the year before. The highest annual figure on record is $9.34M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.44M | -14.8% |
| FY2024 | Dec 31, 2024 | $6.39M | -16.8% |
| FY2023 | Dec 31, 2023 | $7.68M | -17.8% |
| FY2022 | Dec 31, 2022 | $9.34M | +14.2% |
| FY2021 | Dec 31, 2021 | $8.17M | +12.7% |
| FY2020 | Dec 31, 2020 | $7.26M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.20M | -1.9% |
| Q1 FY2026 | Mar 31, 2026 | $1.26M | -14.9% |
| Q4 FY2025 | Dec 31, 2025 | $1.33M | +27.0% |
| Q3 FY2025 | Sep 30, 2025 | $1.40M | +18.3% |
| Q2 FY2025 | Jun 30, 2025 | $1.23M | -39.5% |
| Q1 FY2025 | Mar 31, 2025 | $1.48M | -30.4% |
| Q4 FY2024 | Dec 31, 2024 | $1.05M | -50.9% |
| Q3 FY2024 | Sep 30, 2024 | $1.19M | -28.8% |
| Q2 FY2024 | Jun 30, 2024 | $2.03M | +25.5% |
| Q1 FY2024 | Mar 31, 2024 | $2.12M | -5.9% |
| Q4 FY2023 | Dec 31, 2023 | $2.14M | -27.1% |
| Q3 FY2023 | Sep 30, 2023 | $1.67M | -37.0% |
| Q2 FY2023 | Jun 30, 2023 | $1.62M | -17.9% |
| Q1 FY2023 | Mar 31, 2023 | $2.26M | +26.0% |
| Q4 FY2022 | Dec 31, 2022 | $2.93M | +97.5% |
| Q3 FY2022 | Sep 30, 2022 | $2.65M | -1.4% |
| Q2 FY2022 | Jun 30, 2022 | $1.97M | +17.7% |
| Q1 FY2022 | Mar 31, 2022 | $1.79M | -23.2% |
| Q4 FY2021 | Dec 31, 2021 | $1.48M | +5.2% |
| Q3 FY2021 | Sep 30, 2021 | $2.69M | +28.0% |
| Q2 FY2021 | Jun 30, 2021 | $1.67M | -19.1% |
| Q1 FY2021 | Mar 31, 2021 | $2.33M | – |
| Q4 FY2020 | Dec 31, 2020 | $1.41M | – |
| Q3 FY2020 | Sep 30, 2020 | $2.10M | – |
| Q2 FY2020 | Jun 30, 2020 | $2.07M | – |
See a number that looks wrong?